文献速递脑血管病

ICTuS 2 试验:急性缺血性卒中血管内低温治疗结果

Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2).
PubMed 文献 · Stroke · 2016-11-10

ICTuS 2 是在静脉重组组织型纤溶酶原激活剂(rt-PA)治疗的急性缺血性卒中患者中评估血管内低温安全性、可行性的随机试验。原计划入组 1600 例,实际入组 120 例后试验提前终止;低温组 63 例、常温组 57 例。90 天改良 Rankin 评分 0–1 分比例低温组 33%、常温组 38%,OR 0.81(95%CI 0.36–1.85);严重不良事件两组相当,死亡与肺炎在低温组数值上更高但置信区间宽。

要点

  • 血管内低温联合冷盐水快速降温在 rt-PA 治疗的缺血性卒中患者中安全可行。
  • 90 天良好功能结局低温组 33% 对常温组 38%,OR 0.81(95%CI 0.36–1.85)。
  • 降低肺炎风险的操作调整未显示效果,但样本量小。

核心结论

  • 血管内低温在 rt-PA 治疗的急性缺血性卒中患者中被证实安全可行,但疗效未显示优势,且降低肺炎风险的方案调整似未奏效。

研究设计与样本

  • 随机对照试验,原计划入组 1600 例,实际入组 120 例后提前终止;低温组 63 例接受低温加抗寒战治疗,常温组 57 例。

主要发现

  • 90 天改良 Rankin 评分 0–1 分:低温组 33%、常温组 38%,OR 0.81(95%CI 0.36–1.85)。
  • 严重不良事件两组发生率相同。
  • 死亡率低温组 15.9%、常温组 8.8%,OR 1.95(95%CI 0.56–7.79)。
  • 肺炎低温组 19%、常温组 10.5%,OR 1.99(95%CI 0.63–6.98)。
  • 冷盐水负荷可改善降温速度,且未出现液体过负荷。

关键数值与推荐

  • 低温方案:静脉 rt-PA 后置入股静脉血管内冷却导管,低温维持 24 小时,随后复温 12 小时。
  • 主要终点:3 个月改良 Rankin 评分 0–1 分。

临床怎么用

  • 对 rt-PA 治疗的急性缺血性卒中患者,血管内低温可作为安全可行的手段,但现有数据不支持其改善功能结局。
  • 实施低温时需关注肺炎与死亡风险信号,尽管本试验样本量小、置信区间宽。

局限性

  • 试验在入组 120 例后提前终止,远低于计划的 1600 例,统计效能不足。
  • 肺炎等不良事件的分析基于小样本,OR 的 95%CI 很宽,结论不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Therapeutic hypothermia is a potent neuroprotectant approved for cerebral protection after neonatal hypoxia-ischemia and cardiac arrest. Therapeutic hypothermia for acute ischemic stroke is safe and feasible in pilot trials. We designed a study protocol to provide safer, faster therapeutic hypothermia in stroke patients. METHODS: Safety procedures and 4°C saline infusions for faster cooling were added to the ICTuS trial (Intravascular Cooling in the Treatment of Stroke) protocol. A femoral venous intravascular cooling catheter after intravenous recombinant tissue-type plasminogen activator in eligible patients provided 24 hours cooling followed by a 12-hour rewarm. Serial safety assessments and imaging were performed. The primary end point was 3-month modified Rankin score 0,1. RESULTS: Of the intended 1600 subjects, 120 were enrolled before the study was stopped. Randomly, 63 were to receive hypothermia plus antishivering treatment and 57 normothermia. Compared with previous studies, cooling rates were improved with a cold saline bolus, without fluid overload. The intention-to-treat primary outcome of 90-day modified Rankin Score 0,1 occurred in 33% hypothermia and 38% normothermia subjects, odds ratio (95% confidence interval) of 0.81 (0.36-1.85). Serious adverse events occurred equally. Mortality was 15.9% hypothermia and 8.8% normothermia subjects, odds ratio (95% confidence interval) of 1.95 (0.56-7.79). Pneumonia occurred in 19% hypothermia versus 10.5% in normothermia subjects, odds ratio (95% confidence interval) of 1.99 (0.63-6.98). CONCLUSIONS: Intravascular therapeutic hypothermia was confirmed to be safe and feasible in recombinant tissue-type plasminogen activator-treated acute ischemic stroke patients. Protocol changes designed to reduce pneumonia risk appeared to fail, although the sample is small. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01123161.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lyden P, Hemmen T, Grotta J, et al. Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke. 2016. PMID: 27834742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。